We, therefore, treated control, Acsl4 TG, and Acsl4 KO mice with the lipophilic antioxidant and ferroptosis-specific inhibitor Ferrostatin-1 (Fer-1) starting one day before TAC surgery and then continued treating the mice with Fer-1 daily for 3 weeks following TAC (Fig. 5j); as a negative control, we found that Fer-1 treatment had no significant effect on cardiac outcome in sham-operated control, Acsl4 TG, or Acsl4 KO mice. The gene discussed is ACSL4; the disease is persistent truncus arteriosus.